Industry News
Biotechnology Industry News
While the Trump administration may…
While the Trump administration may be pivoting away from certain vaccinations, it is pushing for the development of antiviral therapies via the launch of a $100 million antiviral therapy development competition.
Trial oversight is shifting from…
Trial oversight is shifting from reactive checks to continuous signal detection. Here’s the framework sponsors are adopting now.
As the first CAR-T treatment for…
As the first CAR-T treatment for an autoimmune disease draws ever closer, the FDA’s Vinay Prasad, M.D., and colleagues have signaled a willingness to support the development of these novel cell therapies with a flexible
Pfizer has pumped the brakes on…
Pfizer has pumped the brakes on six early-stage assets, including three being tested in ulcerative colitis.
Exxel Pharma is eyeing a listing…
Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to deliver in the clinic.
Patients in a phase 2b trial kept…
Patients in a phase 2b trial kept losing weight after switching to monthly dosing of Pfizer’s GLP-1 receptor agonist, providing early validation of the drugmaker’s $10 billion bet on Metsera.
A phase 2a trial of NMD Pharma’s…
A phase 2a trial of NMD Pharma’s rare disease prospect ignaseclant has missed its primary endpoint. But, with patients improving on multiple secondary endpoints, the biotech is accelerating development of the drug candidate.
GSK is trimming its R&D team,…
GSK is trimming its R&D team, a move expected to affect fewer than 50 workers in the U.K. and fewer than 70 staffers in the U.S.
Novo Nordisk’s GLP-1/amylin…
Novo Nordisk’s GLP-1/amylin combo has topped blockbuster semaglutide in a phase 3 Type 2 diabetes trial, though CagriSema still didn't hit the 25% weight loss mark that the Danish pharma had previously laid out for
H1 CEO Ariel Katz shares how AI,…
H1 CEO Ariel Katz shares how AI, regulation and pricing shifts are changing clinical trials and commercialization.
Wave Life Sciences has the fate of…
Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not to take over development of WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency (AATD),
Daiichi Sankyo’s development of…
Daiichi Sankyo’s development of ADCs continues to hit turbulence. The company has experienced two latest hiccups: the discontinuation of internal development of a next-wave candidate featuring its second ADC platform, and yet another delay for
Having already secured regional…
Having already secured regional rights to vTv Therapeutics’ inflammation drug, China’s Newsoara is fronting $20 million to take ownership of the clinical-stage asset across the rest of the world.
Skye Bioscience has published…
Skye Bioscience has published 52-week data on its investigational obesity drug combination, linking the cocktail to 22.3% total weight loss as it works to recover from its failure to hit the primary endpoint.
Roche is continuing its return to…
Roche is continuing its return to the RNAi space by paying $200 million for the worldwide license to one of SanegeneBio’s programs.
Sanofi’s pipeline features a…
Sanofi’s pipeline features a number of once-hyped candidates that are struggling to deliver in the clinic, and the latest mixed phase 3 data from venglustat continue this trend.
As biotech and other sectors of…
As biotech and other sectors of the life sciences industry espouse cautious optimism for a stabler financing environment in 2026, the steady influx of new funds in the space suggests things are trending in a
The FDA warned Corcept…
The FDA warned Corcept Therapeutics that it would face significant hurdles if it submitted its lead rare disease asset for approval, contradicting the biotech’s claims that the candidate’s eventual rejection came as a shock.
Moderna Chief Medical Officer…
Moderna Chief Medical Officer Jacqueline Miller, M.D., is stepping down after a little more than a year in the role. Meanwhile, the mRNA specialist is welcoming a new chief development officer in the form of
Chugai Pharmaceutical has dropped…
Chugai Pharmaceutical has dropped its only clinical candidate that was developed with the aid of its artificial intelligence drug discovery tool but is not giving up on the technology as a method to power its